NCT05070247 2026-01-22A Study of TAK-500 With or Without Pembrolizumab in Adults With Select Locally Advanced or Metastatic Solid TumorsTakedaPhase 1/2 Terminated61 enrolled 29 charts
NCT06603987 2025-11-19Using CICS-1 and SPM-011 and ï¼»18Fï¼½FBPA Commissioned by CICS and Sumitomo Heavy Industries and STELLA PHARMAStella Pharma CorporationPhase 1/2 Enrolling by invitation30 enrolled
NCT02414269 2025-10-08Malignant Pleural Disease Treated With Autologous T Cells Genetically Engineered to Target the Cancer-Cell Surface Antigen MesothelinMemorial Sloan Kettering Cancer CenterPhase 1/2 Active not recruiting113 enrolled
NCT03717415 2024-12-27A Study of Rebastinib (DCC-2036) in Combination With Carboplatin in Patients With Advanced or Metastatic Solid TumorsDeciphera Pharmaceuticals, LLCPhase 1/2 Terminated70 enrolled 24 charts
NCT05500508 2024-12-24Oral AMXT 1501 Dicaprate in Combination With IV DFMOAminex Therapeutics, Inc.Phase 1/2 Terminated15 enrolled
NCT01291420 2024-12-09Dendritic Cell Vaccination for Patients with Solid TumorsUniversity Hospital, AntwerpPhase 1/2 Completed48 enrolled
NCT04913337 2024-10-02Study of NGM707 As Monotherapy and in Combination with Pembrolizumab in Advanced or Metastatic Solid Tumor MalignanciesNGM Biopharmaceuticals, IncPhase 1/2 Active not recruiting179 enrolled
NCT00002465 2013-11-06High-Dose Megestrol in Treating Patients With Metastatic Breast Cancer, Endometrial Cancer, or MesotheliomaNational Cancer Institute (NCI)Phase 1/2 Unknown